Association between baseline lipoprotein (a) levels and restenosis after coronary stenting: Meta-analysis of 9 cohort studies

Atherosclerosis

Volumn 227, Issue 2, 2013, Pages 360-366

  Qin, Shan yu ^a   Liu, Jie ^b   Jiang, Hai xing ^a   Hu, Bang li ^c   Zhou, You ^d   Olkkonen, Vesa M ^d  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^b PEOPLE'S HOSPITAL OF GUANGXI ZHUANG AUTONOMOUS REGION   (China)

^c Guangxi Science and Technology Information Research Institute   (China)

^d MINERVA FOUNDATION INSTITUTE FOR MEDICAL RESEARCH   (Finland)

Author keywords

95 CI; BMS; CAD; Coronary stenting; DES; ISR; Lipoprotein (a); Lp(a); Meta analysis; PCI; Restenosis; SD; SMD

Indexed keywords

LIPOPROTEIN;

AGE; ARTICLE; ASIAN; CAUCASIAN; COCHRANE LIBRARY; CORONARY STENT; CORRELATIONAL STUDY; DRUG ELUTING STENT; EMBASE; ENZYME LINKED IMMUNOSORBENT ASSAY; ETHNICITY; HUMAN; LIPOPROTEIN BLOOD LEVEL; MEDLINE; META ANALYSIS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RACE; RESTENOSIS; TURBIDIMETRY;

ANGIOPLASTY, BALLOON, CORONARY; ASIAN CONTINENTAL ANCESTRY GROUP; CLINICAL TRIALS AS TOPIC; COHORT STUDIES; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; HUMANS; LIPOPROTEIN(A); MIDDLE AGED; MULTIVARIATE ANALYSIS;

EID: 84875051522     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.01.014     Document Type: Article

References (49)

1. Cosgrave J., Melzi G., Corbett S., et al. Comparable clinical outcomes with paclitaxel- and sirolimus-eluting stents in unrestricted contemporary practice. J Am Coll Cardiol 2007, 49:2320-2328.
2. Morice M.C., Serruys P.W., Sousa J.E., et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002, 346:1773-1780.
3. Moses J.W., Leon M.B., Popma J.J., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003, 349:1315-1323.
4. Grewe P.H., Deneke T., Machraoui A., et al. Acute and chronic tissue response to coronary stent implantation: pathologic findings in human specimen. J Am Coll Cardiol 2000, 35:157-163.
5. Hoffmann R., Mintz G.S., Dussaillant G.R., et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation 1996, 94:1247-1254.
6. Mitra A.K., Agrawal D.K. In stent restenosis: bane of the stent era. J Clin Pathol 2006, 59:232-239.
7. Grainger D.J., Kirschenlohr H.L., Metcalfe J.C., et al. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science 1993, 260:1655-1658.
8. Hackshaw A., Kirkwood A. Interpreting and reporting clinical trials with results of borderline significance. BMJ 2011, 343:d3340.
9. Kamitani T., Taniguchi T., Miyai N., et al. Association between plasma lipoprotein(a) concentration and restenosis after stent implantation. Circ J 2005, 69:644-649.
10. Morita Y., Himeno H., Yakuwa H., et al. Serum lipoprotein(a) level and clinical coronary stenosis progression in patients with myocardial infarction: re-revascularization rate is high in patients with high-Lp(a). Circ J 2006, 70:156-162.
11. Zairis M.N., Ambrose J.A., Manousakis S.J., et al. The impact of plasma levels of C-reactive protein, lipoprotein (a) and homocysteine on the long-term prognosis after successful coronary stenting: the Global Evaluation of New Events and Restenosis after Stent Implantation Study. J Am Coll Cardiol 2002, 40:1375-1382.
12. Moher D., Liberati A., Tetzlaff J., et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009, 6:e1000097.
13. Vandenbroucke J.P., Von Elm E., Altman D.G., et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Gac Sanit 2009, 23:158.
14. Stroup D.F., Berlin J.A., Morton S.C., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000, 283:2008-2012.
15. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
16. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558.
17. Thompson S.G., Higgins J.P. How should meta-regression analyses be undertaken and interpreted?. Stat Med 2002, 21:1559-1573.
18. Egger M., Davey Smith G., Schneider M., et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
19. Begg C.B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101.
20. Li B., Zhang L.H., Yang X.G., et al. Postprocedural serum sLOX-1 levels are associated with coronary in-stent restenosis in patients with stable coronary artery disease. Coron Artery Dis 2011, 22:259-263.
21. Gazzaruso C., Garzaniti A., Falcone C., et al. Restenosis after intracoronary stent placement: can apolipoprotein(a) polymorphism play a role?. Int J Cardiol 2003, 87:91-98.
22. Gazzaruso C., Garzaniti A., Falcone C., et al. Lipoprotein(a), apolipoprotein(a) polymorphism and restenosis after intracoronary stent placement in type 2 diabetic patients. J Diabetes Complications 2003, 17:135-140.
23. Ribichini F., Steffenino G., Dellavalle A., et al. Plasma lipoprotein(a) is not a predictor for restenosis after elective high-pressure coronary stenting. Circulation 1998, 98:1172-1177.
24. Gao J., Cui R.Z., Liu Y., et al. Relationship of interleukin-10 gene polymorphism with restenosis after percutaneous coronary intervention in Chinese. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2011, 28:42-46.
25. Hu J., Shen W.F., Zhang J.S., et al. The relationship between serum uric acid and intracoronary in -stent restenosis. J Clin Cardiovasc 2002, 18:359-360.
26. Khosravi A., Pourmoghaddas M., Ziaie F., et al. Does lipoprotein (a) level have a predictive value in restenosis after coronary stenting?. Int J Prev Med 2011, 2:158-163.
27. Li J.X., Ryouzyutsu T., Zyuusi M., et al. Relationship between serum Lipoprotein(a) concentration and restenosis after elective coronary stenting. J Fourth Mil Med Univ 2007, 28:267-269.
28. Qi D.D., Li M.W., Gao C.Y., et al. Relation of apolipoprotein(a) with restenosis after coronary stenting. Clin Focus 2009, 24:965-966.
29. Yang X.Z. Relationship between coronary stent restenosis and blood concentration of Lp(a). Chin J Misdiagn 2010, 10:5035-5036.
30. Ip J.H., Fuster V., Israel D., et al. The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty. J Am Coll Cardiol 1991, 17:77B-88B.
31. Hou J., Qi H., Zhang M., et al. Development of lipid-rich plaque inside bare metal stent: possible mechanism of late stent thrombosis? an optical coherence tomography study. Heart 2010, 96:1187-1190.
32. Argraves K.M., Kozarsky K.F., Fallon J.T., et al. The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor. J Clin Invest 1997, 100:2170-2181.
33. Kojima S., Harpel P.C., Rifkin D.B. Lipoprotein (a) inhibits the generation of transforming growth factor beta: an endogenous inhibitor of smooth muscle cell migration. J Cell Biol 1991, 113:1439-1445.
34. Caplice N.M., Panetta C., Peterson T.E., et al. Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis. Blood 2001, 98:2980-2987.
35. Miyata M., Biro S., Kaieda H., et al. Lipoprotein(a) stimulates the proliferation of cultured human arterial smooth muscle cells through two pathways. FEBS Lett 1995, 377:493-496.
36. Igarashi Y., Aizawa Y., Satoh T., et al. Predictors of adverse long-term outcome in acute myocardial infarction patients undergoing primary percutaneous transluminal coronary angioplasty: with special reference to the admission concentration of lipoprotein (a). Circ J 2003, 67:605-611.
37. Banerjee D., Wong E.C., Shin J., et al. Racial and ethnic variation in lipoprotein (a) levels among Asian Indian and Chinese patients. J Lipids 2011, 2011:291954.
38. Schmidt K., Kraft H.G., Parson W., et al. Genetics of the Lp(a)/apo(a) system in an autochthonous Black African population from the Gabon. Eur J Hum Genet 2006, 14:190-201.
39. Lanktree M.B., Anand S.S., Yusuf S., et al. Comprehensive analysis of genomic variation in the LPA locus and its relationship to plasma lipoprotein(a) in South Asians, Chinese, and European Caucasians. Circ Cardiovasc Genet 2010, 3:39-46.
40. Haery C., Sachar R., Ellis S.G. Drug-eluting stents: the beginning of the end of restenosis?. Cleve Clin J Med 2004, 71:815-824.
41. Kwon J.S., Kim Y.S., Cho A.S., et al. Origin of restenosis after drug-eluting stent implantation in hyperglycemia is inflammatory cells and thrombus. J Atheroscler Thromb 2011, 18:604-615.
42. McFadden E.P., Stabile E., Regar E., et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004, 364:1519-1521.
43. Park S.H., Rha S.W., Kim J.Y., et al. Impact of ApoB/ApoA-I ratio on two-year clinical outcomes in patients undergoing percutaneous coronary intervention with drug-eluting stents, JACC.TCT 2011, vol. 58. p. B69.
44. Gibson C.M., Karmpaliotis D., Kosmidou I., et al. Comparison of effects of bare metal versus drug-eluting stent implantation on biomarker levels following percutaneous coronary intervention for non-ST-elevation acute coronary syndrome. Am J Cardiol 2006, 97:1473-1477.
45. Hoover-Plow J., Hart E., Gong Y., et al. A physiological function for apolipoprotein(a): a natural regulator of the inflammatory response. Exp Biol Med (Maywood) 2009, 234:28-34.
46. Marcovina S.M., Albers J.J., Scanu A.M., et al. Use of a reference material proposed by the international federation of clinical chemistry and laboratory medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin Chem 2000, 46:1956-1967.
47. Levine D.M., Sloan B.J., Donner J.E., et al. Automated measurement of lipoprotein(a) by immunoturbidimetric analysis. Int J Clin Lab Res 1992, 22:173-178.
48. Lewis C.M., Knight J. Introduction to genetic association studies. Cold Spring Harb Protoc 2012, 2012:297-306.
49. Han B., Eskin E. Random-effects model aimed at discovering associations in meta-analysis of genome-wide association studies. Am J Hum Genet 2011, 88:586-598.